Business

Astellas reports 1-year safety data of fezolinetant for the treatment of menopausal symptoms

Astellas headquarters for the Americas is located in Northbrook, Illinois, USA.

JHVEPhoto / iStock Editorial via Getty Images

Astellas Pharma (OTCPK: ALPMF) (OTCPK: ALPMY) report data from a phase 3 trial of oral fezolinetant for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause in women in mainland China.

The company said The primary goal of the 52-week study, called MOONLIGHT 3, was the frequency and severity of adverse events (AEs), which were generally consistent with previous phase 3 studies of fezolinetant.

VMS is often referred to as hot flashes or hot flashes, and night sweats are common symptoms of menopause.

Trial evaluating fezolinetant 30 mg orally once daily in 150 women.

Ahsan Arozullah, senior vice president and regional head of Developmental Therapies, Astellas said: “The top results from the MOONLIGHT 3 study are very encouraging and, according to initial assessment, further support the the long-term safety of fezlinetant.

Astellas said the result will have no impact on its financial projections for the current financial year ending March 31, 2023.

The company notes that in the United States, a new drug application for fezolinetant to treat moderate to severe VMS associated with menopause is under review.

Fezolinetant has achieved the main goal of the phase 3 trial, known as SKYLIGHT 4but failed in another phase 3 study called MOONLIGHT-1.

Source link

news7h

News7h: Update the world's latest breaking news online of the day, breaking news, politics, society today, international mainstream news .Updated news 24/7: Entertainment, Sports...at the World everyday world. Hot news, images, video clips that are updated quickly and reliably

Related Articles

Back to top button